Developer docs
API playgroundTry for free, no card

Search company profiles

Orbicular Pharmaceutical Technologies

Full company profile

uuid0002qis

Namestring
Orbicular Pharmaceutical Technologies
Legal namestring
Orbicular Pharmaceutical Technologies Pvt. Ltd.
Websiteurl
orbicular.co.in
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Orbicular Pharmaceutical Technologies (Pvt. Ltd.) is a Hyderabad, India-based specialty pharmaceutical product development company founded in 2010 that develops complex generic and specialty pharmaceutical dosage forms and out-licenses them to global pharmaceutical partners for commercialization. The company employs 251-500 staff including 200+ specialized scientists and operates under a Quality-by-Design framework with QMS ISO 9001:2008 certification.

Its core technology platform spans five complex dosage-form pillars defined by its CI-TOP SPIN strategy: Complex Injectables (microspheres, nano suspensions and emulsions, liposomes, high-end peptides, depot suspension injections, device-based peptide injections), Topicals (ointments, creams, gels, solutions, foams), Ophthalmics (gels, micro-emulsions, suspensions, preservative-free systems), Parenterals and Niche Injectibles (prefilled syringes, lyophilized injectables, high-potency compounds including hormones, cytotoxics, peptides, prostaglandins), and Sprays and Inhalations (nasal sprays, inhalation solutions). Leadership team members collectively hold 47+ granted U.S. patents and 20+ PCT applications, with prior experience at Strides, Dr. Reddy's, Mylan, Zydus Cadila, and Wockhardt.

The company operates a partnership-led, asset-light business model with two revenue streams: (i) late-stage out-licensing of developed products to global pharmaceutical partners in exchange for upfront payments, milestone payments, and royalties, and (ii) development service contracts for projects matching its capabilities. Notable commercialized assets include generic semaglutide injection (g-Ozempic) licensed to Apotex with US FDA Tentative Approval and Health Canada Notice of Compliance in 2026, generic liraglutide injection (g-Saxenda) launched in the US via Cipla in February 2026, and a dermatology joint venture with Alembic. The company operates a multi-party ecosystem with Shaily Engineering Plastics (pen-device platform), OneSource Specialty Pharma (CDMO manufacturing), and Gland Pharma (co-development). It received $20M from Tata Capital Healthcare Fund II in May 2024.

Short descriptiontext

Orbicular Pharmaceutical Technologies is a Hyderabad-based specialty pharmaceutical R&D company that develops complex generics across injectables, topicals, ophthalmics, parenterals, and inhalation dosage forms, out-licensing late-stage products to global pharma partners like Apotex and Cipla for commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceutical development, complex generic formulations, injectable drug development, pharmaceutical out-licensing, contract pharmaceutical research
Industry4 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Specialty Pharmaceutical Development
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Licensing
TypeLicensing Royalties
Description

Developing niche generic and specialty pharmaceutical products and licensing them at late stages to global partners who commercialize the products in their respective markets. Revenue generated through upfront payments, milestone payments, and royalties on commercialized products.

orbicular.co.in
2Product Development Services
TypeProfessional Services
Description

Providing outsourcing partnership services for pharmaceutical companies for projects that fit Orbicular's service capabilities. Revenue generated through development fees and service contracts.

orbicular.co.in
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Orbicular Pharmaceutical Technologies is a specialty pharmaceutical R&D company that develops niche and complex generic pharmaceutical dosage forms — including complex injectables, topicals, ophthalmics, parenterals, nasal sprays, and inhalations — and licenses the late-stage developed products to global pharmaceutical partners who handle commercialization across regulated and emerging markets. The company operates a partnership-driven model combining formulation development, IP/regulatory strategy, technology transfer, and co-development services for global drug manufacturers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Successfully obtained US FDA Tentative Approval and Health Canada Notice of Compliance for generic semaglutide injection - first such approvals for generic Ozempic in Canada
+2 more records
Product overview1 text field

Orbicular Pharmaceutical Technologies is a specialty pharmaceutical R&D company that develops complex generic and specialty pharmaceutical products across five core dosage form categories: Complex Injectables (microspheres, nano-formulations, liposomes, high-end peptides, depot injections, device-based peptide injections), Topicals (ointments, creams, gels, foams), Ophthalmics (gels, micro-emulsions, suspensions), Parenterals & Niche Injectibles (prefilled syringes, lyophilized injectables, high-potency compounds), and Sprays & Inhalations (nasal sprays, inhalation solutions). The company operates a partnership-driven business model, licensing late-stage developed products to global pharmaceutical partners. Notable products include generic semaglutide injection (g-Ozempic) with USFDA and Health Canada approvals, and generic liraglutide injection (generic Saxenda) approved for the US market.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-21
Description

Strategic partnership using Shaily's proprietary ShailyPen Neo spring-driven pen injector platform for generic semaglutide injection. The combination product received USFDA Tentative Approval, Health Canada Notice of Compliance, and India CDSCO approval. ShailyPen Neo is among a rare class of commercially available spring-driven pen injectors globally, offering full compatibility with ISO-standard 3 mL cartridges.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

Strategic partnership with Apotex for development and commercialization of generic semaglutide injection (generic Ozempic). The product received Health Canada Notice of Compliance and US FDA Tentative Approval. Apotex commercializes the product in Canada as Apo-Semaglutide Injection in 2mg and 4mg prefilled pen formats. This represents back-to-back G7 regulatory authorizations for an entirely India-developed product.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-04-27
Description

Collaborative partnership involving combined scientific, regulatory, and manufacturing capabilities for generic Infuvite Pediatric and Adult Injection products. Apotex served as the ANDA sponsor leading US commercialization while Orbicular and Gland Pharma contributed to development and manufacturing.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-04-21
Description

CDMO partnership where OneSource provides end-to-end manufacturing capabilities from its US-FDA approved facility in Bangalore, India. Orbicular leads product development and technical program for complex peptide products including generic semaglutide injection. The collaboration ensures reliable commercial supply to the US market pending final approval.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-02-27
Description

Partnership for generic Liraglutide Injection (generic Saxenda) launch in the US market for weight management therapy. The launch targets the US GLP-1 weight management market valued at approximately $127 million, strengthening Cipla's US portfolio as one of the few companies offering generic versions of both Victoza and Saxenda.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Major Indian generic and specialty pharmaceutical company with global reach including US generics and respiratory/inhalation franchises. Direct peer and Orbicular's commercialization partner for generic liraglutide in the US.

TypeDirect peer
Description

Indian specialty pharma company with strong complex generics, dermatology, and respiratory franchises. Direct peer with overlapping specialty dosage-form capabilities and global partnership model.

3Endo International
TypeBroad incumbent
Description

US specialty pharmaceutical company historically focused on sterile injectables, generics, and complex dosage forms. Broader incumbent with comparable specialty injectable portfolio and licensing/partnership model.

TypeDirect peer
Description

US-based specialty generics developer focused on complex dosage forms including injectables, topicals, and ophthalmics. Direct peer with comparable business model of developing niche, complex generics for licensing or distribution.

TypeEmerging player
Description

Indian biopharmaceutical company specializing in biosimilars, generic peptides, and complex injectables. Emerging peer with comparable peptide injectable focus, including programs in GLP-1 analogues.

TypeDirect peer
Description

Canadian-headquartered generic pharmaceutical company with significant complex generics and specialty portfolio. Direct peer and Orbicular's lead commercialization partner for generic semaglutide in Canada and the US.

TypeBroad incumbent
Description

Large Indian pharmaceutical company with broad generic and specialty pharma operations including injectables and complex formulations. Broader incumbent — Orbicular's founders came from Dr. Reddy's leadership, and DRL competes across many of the same dosage forms and geographies.

TypeDirect peer
Description

Indian-headquartered pharma services and CDMO with strong complex injectable and specialty formulation capabilities. Direct peer in the Indian complex-generics development and manufacturing services space.

TypeDirect peer
Description

Indian specialty and generic pharmaceutical company. Direct peer and JV partner — Orbicular and Alembic operate a dermatology joint venture, and both target complex generics and specialty pharma in the Indian and global markets.

TypeBroad incumbent
Description

One of India's largest generic pharma companies with significant injectable and complex generics exposure in regulated markets. Broader incumbent competing with Orbicular's partners and itself developing complex generics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orbicular Pharmaceutical Technologies

Specialty Pharmaceutical Developmentorbicular.co.in

Orbicular Pharmaceutical Technologies is a Hyderabad-based specialty pharmaceutical R&D company that develops complex generics across injectables, topicals, ophthalmics, parenterals, and inhalation dosage forms, out-licensing late-stage products to global pharma partners like Apotex and Cipla for commercialization.

What Orbicular Pharmaceutical Technologies does

Orbicular Pharmaceutical Technologies (Pvt. Ltd.) is a Hyderabad, India-based specialty pharmaceutical product development company founded in 2010 that develops complex generic and specialty pharmaceutical dosage forms and out-licenses them to global pharmaceutical partners for commercialization. The company employs 251-500 staff including 200+ specialized scientists and operates under a Quality-by-Design framework with QMS ISO 9001:2008 certification.

Its core technology platform spans five complex dosage-form pillars defined by its CI-TOP SPIN strategy: Complex Injectables (microspheres, nano suspensions and emulsions, liposomes, high-end peptides, depot suspension injections, device-based peptide injections), Topicals (ointments, creams, gels, solutions, foams), Ophthalmics (gels, micro-emulsions, suspensions, preservative-free systems), Parenterals and Niche Injectibles (prefilled syringes, lyophilized injectables, high-potency compounds including hormones, cytotoxics, peptides, prostaglandins), and Sprays and Inhalations (nasal sprays, inhalation solutions). Leadership team members collectively hold 47+ granted U.S. patents and 20+ PCT applications, with prior experience at Strides, Dr. Reddy's, Mylan, Zydus Cadila, and Wockhardt.

The company operates a partnership-led, asset-light business model with two revenue streams: (i) late-stage out-licensing of developed products to global pharmaceutical partners in exchange for upfront payments, milestone payments, and royalties, and (ii) development service contracts for projects matching its capabilities. Notable commercialized assets include generic semaglutide injection (g-Ozempic) licensed to Apotex with US FDA Tentative Approval and Health Canada Notice of Compliance in 2026, generic liraglutide injection (g-Saxenda) launched in the US via Cipla in February 2026, and a dermatology joint venture with Alembic. The company operates a multi-party ecosystem with Shaily Engineering Plastics (pen-device platform), OneSource Specialty Pharma (CDMO manufacturing), and Gland Pharma (co-development). It received $20M from Tata Capital Healthcare Fund II in May 2024.

Orbicular Pharmaceutical Technologies firmographics

Firmographics
Name
Orbicular Pharmaceutical Technologies
Legal name
Orbicular Pharmaceutical Technologies Pvt. Ltd.
Website
https://orbicular.co.in
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
251–500 employees
Short description
Orbicular Pharmaceutical Technologies is a Hyderabad-based specialty pharmaceutical R&D company that develops complex generics across injectables, topicals, ophthalmics, parenterals, and inhalation dosage forms, out-licensing late-stage products to global pharma partners like Apotex and Cipla for commercialization.
Ownership category
akta.pro rank

Orbicular Pharmaceutical Technologies industry classification

Industry
Product category
Specialty Pharmaceutical Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Specialty pharmaceutical development
  • Complex generic formulations
  • Injectable drug development
  • Pharmaceutical out-licensing
  • Contract pharmaceutical research

Where Orbicular Pharmaceutical Technologies is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices1 record

Markets served

Orbicular Pharmaceutical Technologies business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Product Licensing: Developing niche generic and specialty pharmaceutical products and licensing them at late stages to global partners who commercialize the products in their respective markets. Revenue generated through upfront payments, milestone payments, and royalties on commercialized products.
  2. Product Development Services: Providing outsourcing partnership services for pharmaceutical companies for projects that fit Orbicular's service capabilities. Revenue generated through development fees and service contracts.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Orbicular Pharmaceutical Technologies product offering

Product offering

Core offering

Orbicular Pharmaceutical Technologies is a specialty pharmaceutical R&D company that develops niche and complex generic pharmaceutical dosage forms — including complex injectables, topicals, ophthalmics, parenterals, nasal sprays, and inhalations — and licenses the late-stage developed products to global pharmaceutical partners who handle commercialization across regulated and emerging markets. The company operates a partnership-driven model combining formulation development, IP/regulatory strategy, technology transfer, and co-development services for global drug manufacturers.

Product overview

Orbicular Pharmaceutical Technologies is a specialty pharmaceutical R&D company that develops complex generic and specialty pharmaceutical products across five core dosage form categories: Complex Injectables (microspheres, nano-formulations, liposomes, high-end peptides, depot injections, device-based peptide injections), Topicals (ointments, creams, gels, foams), Ophthalmics (gels, micro-emulsions, suspensions), Parenterals & Niche Injectibles (prefilled syringes, lyophilized injectables, high-potency compounds), and Sprays & Inhalations (nasal sprays, inhalation solutions). The company operates a partnership-driven business model, licensing late-stage developed products to global pharmaceutical partners. Notable products include generic semaglutide injection (g-Ozempic) with USFDA and Health Canada approvals, and generic liraglutide injection (generic Saxenda) approved for the US market.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Successfully obtained US FDA Tentative Approval and Health Canada Notice of Compliance for generic semaglutide injection - first such approvals for generic Ozempic in Canada
  • +2 more outcomes

Companies that use Orbicular Pharmaceutical Technologies

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Orbicular Pharmaceutical Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Orbicular Pharmaceutical Technologies partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, flagship, supporting and major.

  • Shaily Engineering PlasticscoreStrategic or Co-development Partner · 21 May 2026Strategic partnership using Shaily's proprietary ShailyPen Neo spring-driven pen injector platform for generic semaglutide injection. The combination product received USFDA Tentative Approval, Health Canada Notice of Compliance, and India CDSCO approval. ShailyPen Neo is among a rare class of commercially available spring-driven pen injectors globally, offering full compatibility with ISO-standard 3 mL cartridges.
  • Apotex Inc.flagshipStrategic or Co-development Partner · 5 May 2026Strategic partnership with Apotex for development and commercialization of generic semaglutide injection (generic Ozempic). The product received Health Canada Notice of Compliance and US FDA Tentative Approval. Apotex commercializes the product in Canada as Apo-Semaglutide Injection in 2mg and 4mg prefilled pen formats. This represents back-to-back G7 regulatory authorizations for an entirely India-developed product.
  • Gland PharmasupportingStrategic or Co-development Partner · 27 April 2026Collaborative partnership involving combined scientific, regulatory, and manufacturing capabilities for generic Infuvite Pediatric and Adult Injection products. Apotex served as the ANDA sponsor leading US commercialization while Orbicular and Gland Pharma contributed to development and manufacturing.
  • OneSource Specialty PharmacoreTechnology or Integration · 21 April 2026CDMO partnership where OneSource provides end-to-end manufacturing capabilities from its US-FDA approved facility in Bangalore, India. Orbicular leads product development and technical program for complex peptide products including generic semaglutide injection. The collaboration ensures reliable commercial supply to the US market pending final approval.
  • Cipla USA Inc.majorStrategic or Co-development Partner · 27 February 2026Partnership for generic Liraglutide Injection (generic Saxenda) launch in the US market for weight management therapy. The launch targets the US GLP-1 weight management market valued at approximately $127 million, strengthening Cipla's US portfolio as one of the few companies offering generic versions of both Victoza and Saxenda.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

Orbicular Pharmaceutical Technologies competitors and assessment

Company assessment

Direct peers

  • Cipla: Major Indian generic and specialty pharmaceutical company with global reach including US generics and respiratory/inhalation franchises. Direct peer and Orbicular's commercialization partner for generic liraglutide in the US.
  • Glenmark Pharmaceuticals: Indian specialty pharma company with strong complex generics, dermatology, and respiratory franchises. Direct peer with overlapping specialty dosage-form capabilities and global partnership model.
  • Lannett Company: US-based specialty generics developer focused on complex dosage forms including injectables, topicals, and ophthalmics. Direct peer with comparable business model of developing niche, complex generics for licensing or distribution.
  • Apotex: Canadian-headquartered generic pharmaceutical company with significant complex generics and specialty portfolio. Direct peer and Orbicular's lead commercialization partner for generic semaglutide in Canada and the US.
  • Piramal Pharma Solutions: Indian-headquartered pharma services and CDMO with strong complex injectable and specialty formulation capabilities. Direct peer in the Indian complex-generics development and manufacturing services space.
  • Alembic Pharmaceuticals: Indian specialty and generic pharmaceutical company. Direct peer and JV partner — Orbicular and Alembic operate a dermatology joint venture, and both target complex generics and specialty pharma in the Indian and global markets.

Broad incumbents

  • Endo International: US specialty pharmaceutical company historically focused on sterile injectables, generics, and complex dosage forms. Broader incumbent with comparable specialty injectable portfolio and licensing/partnership model.
  • Dr. Reddy's Laboratories: Large Indian pharmaceutical company with broad generic and specialty pharma operations including injectables and complex formulations. Broader incumbent — Orbicular's founders came from Dr. Reddy's leadership, and DRL competes across many of the same dosage forms and geographies.
  • Aurobindo Pharma: One of India's largest generic pharma companies with significant injectable and complex generics exposure in regulated markets. Broader incumbent competing with Orbicular's partners and itself developing complex generics.

Emerging players

  • Biocon: Indian biopharmaceutical company specializing in biosimilars, generic peptides, and complex injectables. Emerging peer with comparable peptide injectable focus, including programs in GLP-1 analogues.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Orbicular Pharmaceutical Technologies compliance and trust

Trust signal

Compliance1 record

Orbicular Pharmaceutical Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orbicular Pharmaceutical Technologies leadership team

Management profile

Number of profiles

Profiles4 records

Orbicular Pharmaceutical Technologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orbicular Pharmaceutical Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orbicular Pharmaceutical Technologies

What does Orbicular Pharmaceutical Technologies do?

Orbicular Pharmaceutical Technologies is a specialty pharmaceutical R&D company that develops niche and complex generic pharmaceutical dosage forms — including complex injectables, topicals, ophthalmics, parenterals, nasal sprays, and inhalations — and licenses the late-stage developed products to global pharmaceutical partners who handle commercialization across regulated and emerging markets. The company operates a partnership-driven model combining formulation development, IP/regulatory strategy, technology transfer, and co-development services for global drug manufacturers.

Is Orbicular Pharmaceutical Technologies a public or private company?

Orbicular Pharmaceutical Technologies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Orbicular Pharmaceutical Technologies founded?

Orbicular Pharmaceutical Technologies was founded in 2010. It employs 251 to 500 people.

Where is Orbicular Pharmaceutical Technologies based?

Orbicular Pharmaceutical Technologies is headquartered in Hyderabad, India, in the Asia region.

How does Orbicular Pharmaceutical Technologies make money?

Two revenue lines are on record. Product Licensing is the primary driver. The others are product Development Services.

Who are Orbicular Pharmaceutical Technologies's main competitors?

Direct peers on record are Cipla, Glenmark Pharmaceuticals, Lannett Company, Apotex, Piramal Pharma Solutions and Alembic Pharmaceuticals. Broad incumbents are Endo International, Dr. Reddy's Laboratories and Aurobindo Pharma. Biocon is listed as an emerging player.

Does Orbicular Pharmaceutical Technologies have an API?

No public API is recorded for Orbicular Pharmaceutical Technologies.

What industry is Orbicular Pharmaceutical Technologies in?

Orbicular Pharmaceutical Technologies's product category is Specialty Pharmaceutical Development. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MintPE majors eye Orbicular Pharma stake, valuation seen up to $1.5 bnPrivate equity firms including Warburg Pincus and CVC Capital Partners have shown early interest in Orbicular Pharmaceutical Technologies, which is exploring a stake sale. The deal could value the Hyderabad-based specialty pharma firm at up to $1.5 billion, with Tata Capital Healthcare Fund likely to exit. The company reported FY26 operating income of ₹525 crore and net profit of ₹53.3 crore.BioSpaceApotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight managementApotex announced it is the first to receive Health Canada approval for SEVMIA, a generic semaglutide injection for chronic weight management. The multi-use pre-filled pen delivers 1 mg doses, and the approval follows Health Canada's recent approval of Apo-Semaglutide Injection. The company aims to expand access to affordable medicines for Canadians.NewswireApotex first to receive Health Canada approval for SEVMIA™, a generic semaglutide for chronic weight managementApotex announced it is the first to receive Health Canada approval for SEVMIA, a generic semaglutide injection for chronic weight management. The multi-use pre-filled pen delivers 1 mg doses, and the approval follows Health Canada's recent approval of Apo-Semaglutide Injection. The company aims to expand access to affordable medicines for Canadians.Express PharmaShaily announces approval, launch of customer combo product with ShailyPen Neo Device TechnologyShaily Engineering Plastics announced that its strategic partner Orbicular Pharmaceutical Technologies, in partnership with their customer, has launched a generic semaglutide injection in Canada using Shaily's proprietary ShailyPen Neo spring-driven pen injector platform. The combination product has received USFDA Tentative Approval, Health Canada Notice of Compliance, and India CDSCO approval, and has been commercially available in India since March 2026. ShailyPen Neo is among a rare class of commercially available spring-driven pen injectors globally, offering full compatibility with ISO-standard 3 mL cartridges.BioSpaceApotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®Health Canada approved Apo-Semaglutide Injection, a generic equivalent of Ozempic, from Apotex, the first Canadian-based company to receive such approval. The product offers two pen formats for type 2 diabetes treatment and will be brought to market in the near future.BioSpaceApotex Announces FDA Approval of Generic Infuvite® Pediatric Injection, Eligible for 180‑day CGT Exclusivity (Single‑Dose Vial), Complementing its Recent Approval of Generic Infuvite Adult InjectionApotex announced FDA approval of generic Infuvite pediatric injection, eligible for 180-day CGT exclusivity for single-dose vial. The approval follows the April 13 approval of the adult injection, expanding access to parenteral nutrition for both adult and pediatric patients.Inc.Shed Pounds, Save Big Bucks: FDA Clears Way for First Low-Price Generic Drug for Weight LossThe FDA has granted tentative approval to Apotex Corp. to market the first generic form of Ozempic (semaglutide injection) in the United States, with final approval expected by 2032 when Novo Nordisk's patents expire. The generic, developed in partnership with India's Orbicular Pharmaceutical Technologies, would entitle Apotex to 180 days of market exclusivity. A University of Liverpool study suggested that mass-produced generic versions could cost less than $3 a month, compared to Ozempic's current list price of nearly $1,000 a month, potentially dramatically expanding patient access to affordable weight-loss therapy.The Globe and MailApotex wins tentative FDA approval for generic Ozempic, drug makers await Health Canada decisionsApotex won tentative FDA approval for a generic Ozempic, six years before the patent expires, with no generic versions approved in Canada yet. The U.S. patent expires in 2032, and Apotex has 180 days of market exclusivity. Health Canada has nine pending generic semaglutide applications, with reviews targeting 180 days.BioSpaceApotex Receives First U.S. FDA Tentative Approval for a Generic Version of Ozempic® (Semaglutide Injection) in Partnership with OrbicularApotex received the first U.S. FDA tentative approval for its generic semaglutide injection, developed with Orbicular. The approval marks a milestone in expanding access to complex peptide therapies. Upon final approval, the product is expected to broaden patient access.